Business
Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline
Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across multiple viruses, today highlighted a series of recent strategic, operational and scientific achievements that underscore accelerating momentum and a clear trajectory toward becoming a clinical-stage company. The Company also outlined upcoming milestones that are expected to drive shareholder value.
About this update from Decoy Therapeutics Inc.
[{"type":"text","content":"Highly differentiated AI-powered D-MAV discovery platform targeting drugdiscovery in the multi-billion-dollar antiviral markets","length":128,"tagName":"p","attribs":{}},{"type":"text","content":"Company to participate in Virtual Investor Closing Bell event to discuss pathforward today at 4:00 PM ET. Access the event here","length":128,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, Mass. and HOUSTON, April 9, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across multiple viruses, today highlighted a series of recent strategic, operational and scientific achievements that underscore accelerating momentum and a clear trajectory toward becoming a clinical-stage company. The Company also outlined upcoming milestones that are expected to drive shareholder value.","length":559,"tagName":"p"},{"type":"image","alt":"Logo (PRNewsfoto/Decoy Therapeutics, Inc)","displaySize":"","headline":null,"caption":"Logo (PRNewsfoto/Decoy Therapeutics, Inc)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":104,"url":"https://media.zenfs.com/en/prnewswire.com/f3867f8a7694a91d3360742d3fdb246a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YyEL5SG8p3qov4E54_d53A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE4Mw--/https://media.zenfs.com/en/prnewswire.com/f3867f8a7694a91d3360742d3fdb246a","width":400,"height":104}},"href":"https://mma.prnewswire.com/media/2859955/Decoy_Therapeutics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Over the past several months, Decoy has executed across multiple fronts, strengthening its capital markets' position, advancing its pipeline and further validating its differentiated D-MAV discovery platform capabilities. These efforts are positioning the Company to potentially realize a number of value creating catalysts in the not-too-distant future.","length":358,"tagName":"p"},{"type":"text","content":""We are executing with urgency and purpose as we advance our pipeline assets to the clinic as expeditiously as possible," said Rick Pierce, Chief Executive Officer of Decoy Therapeutics. "We are undertaking substantive steps to achieve these goals and look forward to kee...